|
| Press Releases |
|
 |
|
| Friday, October 30, 2020 |
|
|
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony. more info >> |
|
| Wednesday, October 28, 2020 |
|
|
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020 |
| Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. more info >> |
|
| Tuesday, September 22, 2020 |
|
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Tuesday, June 9, 2020 |
|
|
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020 |
| The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. more info >> |
|
| Thursday, April 9, 2020 |
|
|
Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis |
| Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025 
Dec 26, 2024 17:11 JST
|
|
|
Annual Surge of 37% in Legal and Compliance Job Roles while overall hiring drops 6% in Singapore: foundit Insights Tracker
Dec 26, 2024 13:45 HKT/SGT
|
|
|
The 25th World LNG Summit & Awards will take place on 2-5 December 2025 in Istanbul, Turkiye
Dec 26, 2024 13:10 HKT/SGT
|
|
|
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
|
|
|
Mazda Production and Sales Results for November 2024
Dec 26, 2024 11:46 JST
|
|
|
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 9:47 JST
|
|
|
Caj Africa Releases Analytical Report on Syria's 2024 Socialist Dynamics
Dec 26, 2024 07:00 HKT/SGT
|
|
|
Spectral Capital Announces Transformation into a Deep Quantum Technology Platform
Dec 25, 2024 10:59 HKT/SGT
|
|
|
Singapore's most anticipated skyhigh destination C.O.T.U officially opens in iconic Marina Bay this holiday season
Dec 25, 2024 08:00 HKT/SGT
|
|
|
From Visionary Talks to Futuristic Robots: VAP Group's Global Blockchain Show Dazzles Dubai
Dec 25, 2024 07:36 HKT/SGT
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 25, 2024 07:25 HKT/SGT
|
|
|
VAP Group's Global AI Show Explores the Future of AI with Over 3,000 Participants
Dec 24, 2024 15:40 HKT/SGT
|
|
|
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
|
|
|
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
|
|
|
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
